Insulet Raises Full-Year Revenue Guidance After Q1 Growth Driven by International Omnipod Surge
Q1 Results Beat: International Omnipod Sales Soar 59.4%
Insulet Corporation (NASDAQ: PODD) delivered a strong start to 2026, reporting first-quarter revenue of $761.7 million—a 33.9% increase over the prior year. The standout driver was international Omnipod revenue, which surged 59.4% to $242.9 million (45.2% in constant currency). U.S. Omnipod sales also rose a robust 28.3% to $515.6 million.
The Omnipod 5 platform continues to anchor Insulet's leadership in tubeless insulin pump technology, as expanded launches brought the product to 19 countries, including five in the Middle East in Q1. The company exceeded the high end of its guidance range for total revenue growth at constant currency, setting the tone for upwardly revised full-year targets.
| Q1 Metric | 2026 | 2025 | Change |
|---|---|---|---|
| Total Revenue (million) | $761.7 | $569.0 | +33.9% |
| Omnipod Revenue (million) | $758.4 | $554.0 | +36.9% |
| U.S. Omnipod (million) | $515.6 | $401.7 | +28.3% |
| International Omnipod (million) | $242.9 | $152.3 | +59.4% |
| Net Income (million) | $91.1 | $35.4 | +157.4% |
| Adjusted EPS | $1.42 | $1.02 | +39.2% |
Margin Expansion and Upbeat Outlook Set the Stage
Profitability also improved, with GAAP operating income rising to $122.1 million (16% of revenue), and adjusted operating income climbing to $133.5 million (17.5% of revenue), up 110 basis points year-over-year. Adjusted net income came in at $99.8 million, or $1.42 per diluted share, a notable jump from the previous year.
Leveraging momentum, Insulet has raised its full-year 2026 revenue guidance from 20–22% growth to 21–23% (constant currency). International growth stands out, with guidance also raised to 26–28%, reflecting both recent launches and heightened demand outside the U.S.
| 2026 Guidance (Constant Currency) | Prior | Current |
|---|---|---|
| Total Revenue Growth | 20% – 22% | 21% – 23% |
| U.S. Omnipod | 20% – 22% | 20% – 22% |
| International Omnipod | 24% – 26% | 26% – 28% |
| Adjusted Operating Margin Expansion | ~100 bps YoY | ~100 bps YoY |
| Adjusted EPS Growth | >25% | >25% |
Product Innovation Continues: New Omnipod 5 Algorithm and Expanded Access
Technology remains a key differentiator for Insulet. In Q1, the company launched a new algorithm update for Omnipod 5, enhancing automated insulin delivery and allowing for more personalized glucose targets (down to 100 mg/dL). Data presented at the ATTD conference confirmed improved time-in-range for users—an important clinical benchmark—with the new setting outperforming higher targets by as much as 20.8 percentage points in time-in-range, without increasing time below range.
Broadening platform connectivity, Insulet completed a limited U.S. rollout of Omnipod 5 with FreeStyle Libre 3 Plus, increasing integration options. The company also advanced its development of a closed-loop system for adults with type 2 diabetes, enrolling participants for pivotal trials and targeting a 510(k) submission in 2027.
Free Cash Flow and Capital Allocation Remain Solid
Insulet’s operational discipline showed in first-quarter free cash flow of $89.5 million—up from $51.6 million in Q1 2025—despite increased R&D and expansion spending. The company repurchased 1.25 million shares in Q1, further returning capital to shareholders.
Key Takeaways: Growth Broadens, Margin Expands, Innovation Drives Momentum
Insulet’s Q1 2026 report underscores accelerating international adoption of its Omnipod system, meaningful margin expansion, and a pipeline of innovation supporting raised full-year guidance. Investors will be watching whether sustained international demand and product launches continue to outpace expectations, and how quickly the company can scale its next-generation offerings, particularly as it targets new diabetes populations.
For more details, Insulet’s conference call replay and full presentation are available via the company’s investor relations site.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI